Recently Diagnosed or Relapsed? Stop Looking For a Miracle Cure, and Use Evidence-Based Therapies To Enhance Your Treatment and Prolong Your Remission

Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.

Click the orange button to the right to learn more about what you can start doing today.

Multiple Myeloma, Low-dose Maintenance Chemotherapy vs. Evidence-based, Non-Toxic Therapies

Share Button

The combination of lenalidomide and dexamethasone synergizes the inhibition of cell proliferation and the induction of apoptosis in multiple myeloma cells

Hello Cancer Coach- I watched your webinar about multiple myeloma (MM) last week because I’m trying to find some answers that my doctor can’t give me.

I was diagnosed with Multiple Myeloma in July 2016.  Since then I underwent induction chemotherapy and an autologous stem cell transplant in May 2017.

Image result for image of low dose maintenance therapy

Now the doctor wants to put me on Revlimid for the rest of my life!!! You don’t know me, but I’m 47…make that 48 (it’s my birthday today 😊)

I’m in shape, I bike or run  about 5-6 times a week. I can say that in a pretty good shape!! I didn’t stop training while I was on chemo. I eat nutritiously as I have been a vegetarian since about 5 years now. I think I have a healthy life!  When I found out I had MM I did  reduce sugar from my meals… This is difficult as I like desert!

I really like your story that I just read on the Burzynski Patient Website.  It seems like you don’t take toxic chemotherapy and haven’t for a longtime now. Is it the case? I just want to know if there’s a chance to get a good life without chemotherapy…

I don’t like the side effects of chemotherapy. I believe that we can fight MM with non-toxic therapies.

Also, Antineoplaton Therapy (ANP) is not available here in Canada. Are you still taking ANP?

Hope to hear from you soon-


Hi Nathalie-
I am sorry to learn of your MM diagnosis though it sounds as though you are doing well. I will address your questions as best I can. 
1) my guess is that your condition (nutrition, frequent exercise, etc.) helped you through both induction chemo as well as your stem cell transplant. These lifestyle therapies should help you manage your MM as well as help you live with low-dose maintenance therapy if you choose to do this. 
2) low-dose Revlimid maintenance therapy has been shown to increase overall survival in MM patients. Yes, low-dose maintenance Revlimid can bring short, long-term and late stage side effects. The risk of secondary cancers also increases.
However, the key to this therapy is the actual dose of Rev. and the side effects that the patients undergoes while on low dose rev. The current “standard-of-care” for MMers is a daily dose of 10mg. There are evidence-based integrative therapies that enhance the efficacy of Revlimid while reducing its toxicity. 
If you continue to exercise, eat well, take anti-MM supplements, take supplements that integrate with revlimid, undergo bone health therapies, etc., then you may feel better as well as getting the benefits of maintenance therapy. 
Yes, there are a lot of “ifs.”
3) No, I haven’t undergone toxic chemotherapy or radiation since 1997. After I finished antineoplaston therapy I followed the non-toxic, anti-MM lifestyle that is the basis for the MM CC program. 
4) Yes, you can fight MM with evidence-based, non-toxic therapies. This is the purpose of the multiple myeloma cancer coaching program. 

Please watch the video below to learn more about the evidence-based, integrative therapies to combat treatment side effects and enhance your chemotherapy.

Let me know if you have any questions. 
Hang in there, 
David Emerson
  • MM Survivor
  • MM Cancer Coach
  • Director PeopleBeatingCancer

Recommended Reading:

Lenalidomide as Maintenance Therapy in Multiple Myeloma After Autologous Stem Cell Transplantation

“In CALGB 100104, among 231 patients randomized to receive lenalidomide vs 229 randomized to receive placebo, median progression-free survival was 33.9 vs 19.0 months… In IFM 2005-02, among 307 lenalidomide patients vs 307 placebo patients, median progression-free survival was 41.2 vs 23.0 months… At updated overall survival analysis in February 2016, median overall survival was 111.0 vs 84.2 months in CALGB 100104 and 105.9 vs 88.1 months in IFM 2005-02.

How It Works- Lenalidomide is a thalidomide (Thalomid) analog with immunomodulatory, antiangiogenic, and antineoplastic properties. It inhibits proliferation and induces apoptosis of certain hematopoietic tumor cells, including mantle cell lymphoma, multiple myeloma, and del(5q) myelodysplastic syndrome in vitro and delays tumor growth in hematopoietic tumor models including multiple myeloma…

The combination of lenalidomide and dexamethasone synergizes the inhibition of cell proliferation and the induction of apoptosis in multiple myeloma cells

The most common adverse events of any grade across both maintenance studies (> 20% of lenalidomide patients) were neutropenia, thrombocytopenia, leukopenia, anemia, upper respiratory tract infection, bronchitis, nasopharyngitis, cough, gastroenteritis, diarrhea, rash, fatigue, asthenia, muscle spasm, and pyrexia. The most common grade 3 or 4 adverse events in the two studies (vs placebo) included neutropenia (59% vs 33% and 54% vs 8%), thrombocytopenia (38% vs 30% and 13% vs 3%), and leukopenia (20% vs 10% and 24% vs 2%).

Serious adverse events occurring in > 4.5% of lenalidomide patients were lung infection and neutropenia. The most common adverse events leading to discontinuation of lenalidomide were thrombocytopenia (2.7%) and neutropenia (2.4%).

In patients receiving lenalidomide maintenance therapy following high-dose intravenous melphalan and autologous stem cell transplant, hematologic second primary malignancies occurred in 7.5% of patients compared to 3.3% of patients receiving placebo…”


Leave a Comment:

Add Your Reply